home / stock / jnj / jnj articles

JNJ Articles, Johnson & Johnson - From 05/16/24

Stock Information
Company Name: Johnson & Johnson
Stock Symbol: JNJ
Market: NYSE
Website: jnj.com
Menu
JNJ JNJ Quote JNJ Short JNJ News JNJ Articles JNJ Message Board
Get JNJ Alerts

News, Short Squeeze, Breakout and More Instantly...
Pfizer, AstraZeneca, Sanofi And Mainz Biomed To Uplevel Europe's Pharma Game | Benzinga

On Sunday, Pfizer (NYSE: PFE) and AstraZeneca Plc (NASDAQ: AZN) were among the pharmaceutical companies who announced they will be investing a...
Johnson & Johnson's Subsidiary Discontinues Some Megadyne Electrodes For Pediatric Use | Benzinga

Johnson & Johnson’s (NYSE:JNJ) medical device subsidiary is pulling its Megadyne Mega Soft Pediatric Patient Return Electrodes follo...

A Look at Pharma ETFs Post Q1 Earnings | Benzinga

The first-quarter results of the healthcare sector have been unimpressive, with earnings of 78% of the sector participants that have reported so fa...

Johnson & Johnson's TARIS Platform - Goldman Sachs Outlines Potential For The Bladder Cancer Therapy | Benzinga

Over the weekend, Johnson & Johnson (NYSE:JNJ) shared data from its TARIS platform assets (TAR-210 and TAR-200) in patients with diff...
Johnson & Johnson Advances Its Two Bladder Cancer Studies, Releases Latest Data | Benzinga

On Sunday, Johnson & Johnson (NYSE:JNJ) ) released updated results from an open-label, multicenter, multi-cohort Phase 1 st...

Comparing Johnson & Johnson With Industry Competitors In Pharmaceuticals Industry | Benzinga

In the fast-paced and cutthroat world of business, conducting thorough company analysis is essential for investors and industry experts. In this ar...

Nasdaq, S&P 500 Futures Rise Ahead Of Apple Earnings: Why This Analyst Thinks 'No Cut' Scenario May Not Be Negative For Market | Benzinga

U.S. stocks look to push ahead on a positive path, now that the Federal Reserve’s rate decision is in the rearview mirror. Major index future...
Johnson & Johnson Wants To Deal With Talc Lawsuit Overhang, Proposes $6.5B Settlement Package | Benzinga

Wednesday, Johnson & Johnson (NYSE:JNJ) announced its intention to proceed with a $6.475 billion settlement to resolve numerous lawsu...

Johnson & Johnson-Partnered Addex Therapeutics' Epilepsy Candidate Fails Mid-Stage Study, Stock Tanks | Benzinga

Monday, Addex Therapeutics (NASDAQ:ADXN) released top-line data from a Phase 2 epilepsy study evaluating adjunctive ADX71149 (JNJ-4041181...

Johnson & Johnson Children's Cough Syrup Contaminated In Some Batches - WHO Poised to Issue Global Alert (Updated) | Benzinga

Editor’s note: We have updated the story with Kenvue’s statement in response to the report in paragraph 7 The World Health Organiz...
Previous 10 Next 10